Jørgensen will step down after eight years as CEO, with a successor search underway while the company reaffirms confidence in ...

Our exclusive poll captures today's top trends and perspectives—shaped by those pharma decision-makers impacted the most.

Welireg marks the first FDA-approved non-surgical treatment option for locally advanced, unresectable, or metastatic ...

Polanco, executive VP and chief commercial officer, Novartis US, and the 2025 Healthcare Businesswomen’s Association Woman of ...

The order pushes drug companies to reduce drug prices in the United States to fall in line with other countries around the ...

Weight-loss and diabetes drugs dominated pharmaceutical spending last year, according to a new report by the American Society ...

The decision follows ongoing investigations into serious adverse events primarily reported in elderly individuals who ...

On Sunday, President Trump posted to Truth Social that he planned on implementing a most-favored-nation policy for ...

Zynyz is the first and only FDA-approved first-line treatment for adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal.

The Avmapki Fakzynja Co-Pack marks the first FDA-approved treatment for adult patients with KRAS-mutated recurrent low-grade ...

Emrelis is the first FDA-approved treatment for previously treated patients with locally advanced or metastatic non-squamous non-small cell lung cancer with high c-Met protein overexpression.

Under the agreement, GSK will acquire BP Asset IX, a subsidiary of Boston Pharmaceuticals, for up to $2 billion in total cash ...